What is the recommended starting dose of ribociclib for an adult with hormone‑receptor‑positive, HER2 (human epidermal growth factor receptor 2)‑negative metastatic breast cancer, and how should the dose be adjusted for hepatic impairment or toxicity?

Ribociclib Dosing for HR+/HER2- Metastatic Breast Cancer

The recommended starting dose of ribociclib for adults with hormone receptor-positive, HER2-negative metastatic breast cancer is 600 mg orally once daily for 21 consecutive days followed by 7 days off (3 weeks on/1 week off schedule), administered in combination with endocrine therapy. 1

Standard Dosing Regimen

Starting Dose: 600 mg once daily (3 weeks on/1 week off) combined with:

• An aromatase inhibitor (AI) for patients who have not relapsed on adjuvant AI or within 12 months of stopping adjuvant AI 2
• Fulvestrant for patients who relapsed on adjuvant AI therapy or within 12 months of stopping adjuvant AI 2

The 600 mg dose is specifically for advanced/metastatic breast cancer, distinct from the 400 mg dose approved for early breast cancer 1, 3, 4.

Dose Modifications for Hepatic Impairment

Hepatic impairment requires careful dose adjustment 1:

• Mild hepatic impairment (Child-Pugh Class A): No dose adjustment necessary
• Moderate hepatic impairment (Child-Pugh Class B): Reduce starting dose to 400 mg once daily
• Severe hepatic impairment (Child-Pugh Class C): Reduce starting dose to 400 mg once daily

The pharmacokinetic data demonstrate approximately 30% increased ribociclib exposure in patients with moderate and severe hepatic impairment compared to normal hepatic function, justifying the dose reduction 5. Patients with liver metastases, history of hepatitis B infection, or fatty liver have significantly higher risk of hepatotoxicity and require closer monitoring 6.

Dose Modifications for Renal Impairment

1:

• Mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m²): No dose adjustment necessary
• Severe renal impairment (eGFR <30 mL/min/1.73 m²): Reduce starting dose to 200 mg once daily

Dose Reductions for Toxicity

Ribociclib has two lower dose levels for toxicity management 1:

• First dose reduction: 400 mg once daily
• Second dose reduction: 200 mg once daily
• If unable to tolerate 200 mg: Discontinue ribociclib

Neutropenia Management

Monitor complete blood counts every 2 weeks for the first 2 cycles, then at the beginning of each subsequent 4 cycles 7, 1:

• Grade 1-2 neutropenia: Continue at current dose
• Grade 3 neutropenia: Hold ribociclib until recovery to Grade ≤2, then resume at same dose
• Grade 3 neutropenia with fever >38.3°C or infection: Hold until recovery to Grade ≤2, then resume at next lower dose level
• Grade 4 neutropenia: Hold until recovery to Grade ≤2, then resume at next lower dose level

Hepatotoxicity Management

Hepatotoxicity is a critical adverse event requiring vigilant monitoring 6, 8:

• Grade 2 hepatotoxicity: Hold ribociclib until recovery to Grade ≤1, then resume at same dose
• Grade 3 hepatotoxicity: Hold until recovery to Grade ≤1, then resume at next lower dose level; if recurs, reduce dose further
• Grade 4 hepatotoxicity: Discontinue ribociclib permanently

Important caveat: If severe hepatotoxicity persists despite holding ribociclib, consider empiric corticosteroid therapy, as case reports demonstrate remarkable response to this intervention 8.

QTc Prolongation Management

Monitor ECG before starting treatment, at approximately day 14 of the first cycle, and at the beginning of the second cycle 1:

• QTcF >480 ms but <500 ms: Hold ribociclib until QTcF <481 ms, then resume at next lower dose
• QTcF ≥500 ms: Hold until QTcF <481 ms, then resume at next lower dose; if recurs, discontinue permanently

Drug Interaction Dose Adjustments

Strong CYP3A inhibitors significantly increase ribociclib exposure 1, 9:

• Avoid concomitant use of strong CYP3A inhibitors when possible
• If unavoidable: Reduce ribociclib dose to 400 mg once daily during coadministration
• After discontinuing the strong inhibitor (after ≥5 half-lives), return to the dose used prior to initiation

Strong CYP3A inducers decrease ribociclib exposure by 74-83% and should be avoided 9.

Clinical Context

Ribociclib must be combined with endocrine therapy—it has not demonstrated single-agent efficacy, unlike abemaciclib 2. The three approved CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) show similar efficacy in metastatic disease, but ribociclib has a distinct toxicity profile with higher rates of hepatotoxicity and QTc prolongation compared to palbociclib 2, 6.

The primary toxicities requiring dose modification are neutropenia (most common), hepatotoxicity, and QTc prolongation 7, 2. Neutropenia is typically uncomplicated and manageable with dose delays and reductions 7.